Xilio Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XLO research report →
Range $98.00000000000001 – $98.00000000000001
Price Chart
About the company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors.
- CEO
- Rene Russo
- IPO
- 2021
- Employees
- 76
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on XLO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $60.69M
- P/E
- -6.19
- PEG
- -0.03
- P/S
- 0.95
- P/B
- 2.48
- EV/EBITDA
- 3.37
- Div Yield
- 0.00%
- Gross Margin
- 99.46%
- Op Margin
- -48.94%
- Net Margin
- -34.06%
- ROE
- -50.77%
- ROIC
- -25.82%
Latest fiscal year · YoY change
- Revenue
- $43.77M+589.9%
- Gross Profit
- $42.23M+565.6%
- Op Income
- $-41,982,000
- Net Income
- $-35,036,000+39.8%
- EPS
- $-4.19+72.5%
- OCF Growth
- +72.8%
- FCF Growth
- +70.1%
- 52W High
- $12.74
- 52W Low
- $6.47
- 50D MA
- $8.96
- 200D MA
- $8.81
- Beta
- -0.12
- RSI (14)
- 54
- Avg Volume
- 34.73K
No earnings-call transcripts are available for XLO yet.
- Free Float
- 35.8%
- Shares Outstanding
- 6.58M
- Float Shares
- 2.36M
of shares held by institutions
37 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Takeda Pharmaceutical Co Ltd | 1.48M | 0 |
| Vanguard Group Inc | 1.26M | 0 |
| Aju Ib Investment Co., Ltd. | 47.70K | ▼ 620.05K |
| Cwm, LLC | 4.21K | ▲ 4.21K |
Held by 23 ETFs
Biggest fund positions in XLO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Bello Akintunde Olatokumbo | other | 5,000 |
| Jun 11, 26 | Shannon James Samuel | other | 5,000 |
| Jun 11, 26 | Curran Daniel J. | other | 5,000 |
| Jun 11, 26 | Xu Yuan | other | 5,000 |
| Jun 11, 26 | ROSS ROBERT W. | other | 5,000 |
| Jun 11, 26 | Bonstein Sara | other | 5,000 |
| Jun 11, 26 | Brennan Aoife | other | 5,000 |
| Apr 15, 26 | Blanchard Cheryl R | other | 10,000 |
| Apr 15, 26 | Blanchard Cheryl R | other | 0 |
| Mar 26, 26 | Shannon James Samuel | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XLO coverage
Recent articles, reports, and earnings notes.
No research on XLO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XLO report →Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
globenewswire.com · Aug 12
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 6
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
globenewswire.com · Jun 29
Cancer Stocks That Are Advancing the Future of Oncology Care
zacks.com · May 18
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
zacks.com · May 12
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
globenewswire.com · May 12
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 7
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.